Weekly Digest - 18-24 Mar 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 18-24 Mar 2023
March 21, 2023: Yescarta / R/R Large B-cell Lymphoma / KITE’S: Yescarta (CAR T-cell Therapy) improves overall survival for R/R Large B-cell Lymphoma patients
- Encouraging OS data reported from Phase 3 ZUMA-7 study of Yescarta vs SOC for initial treatment of adult patients with R/R Large B-cell Lymphoma
- ZUMA-7 is regarded as a landmark trial as it’s the first and largest Phase 3 study of any CAR T-cell therapy, with the longest, follow up
- It demonstrated superior event-free survival (EFS) to historical SOC treatment i.e., 8.3 months vs. 2.0 months
- Detailed data will be presented later this year at an upcoming scientific meeting
- In 30 years Yescarta is the first and only treatment with improved OS for the initial treatment of R/R LBCL patients
- Yescarta demonstrated a 2.5-fold increase in patients who were alive at two years without any cancer progression or additional cancer treatment compared to SOC
